A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

NCT01969942 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No subjects meeting study inclusion were enrolled.

Conditions

Ewing Sarcoma

Interventions

BIOLOGICAL: allogeneic stem cell transplantation
DRUG: Clyclophosphamide
DRUG: Fludarabina
DRUG: Busulfan
DRUG: Melphalan

Sponsor

University of Louisville